So let's get started with $100,000 in play money. Looking to buy biotech stocks at today's prices, and keep some figurative cash on hand for future purchases. We'll start slowly.
TELK 806 shares at $ 18.62 (Total Cost: $15007.72)
MLNM 983 shares at $ 10.17 (Total Cost: $ 9997.11)
OSIP 356 shares at $ 28.09 (Total Cost: $10000.04)
Speedel 91 shares at $110.08 (Total Cost: $10017.28)
*(Converted from 138.90 CHF at 0.7925 US/CHF)
GTCB 2873 shares at $ 1.74 (Total Cost: $ 4999.02)
GNVC 1169 shares at $ 1.71 (Total Cost: $ 1998.99)
CTIC 966 shares at $ 2.07 (Total Cost: $ 1999.62)
Stock Total $54019.78
Cash On Hand $45980.22
For the above, TELK is being followed for the Telcyta pivotal trial results.
OSIP because Tarceva is useful, they will likely get some future DP-IV royalties... so maybe that's a purchase because it has been beat down.
As for MLNM, Velcade is still useful. And finally the company has trimmed enough where the pipeline is a little more interesting.
Speedel, for its renin inhibitor.
GTCB is a platform company, same as GNVC. GNVC's vaccine business is probably more interesting than the slow-as-molasses TNFerade program.
CTIC is a flier for pixantrone only. It's a race between the CEO's blowing of money on Xyotax versus the pixantrone trial getting fully enrolled and maturing. Hope the pix results come first, but the $2000 allowance shows how confident I am in management's ability to cash in on every last cent in the company account.
Drugs under private development that we'll follow:
Prolyl Hydroxylase inhibitor from Fibrogen (private).
I'll leave this blog open to comments and questions. I believe the email is listed on the profile. I'll try and post thoughts and updates as time permits. Hopefully I can update the portfolio performance once a month.
No comments:
Post a Comment